Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine Regimen for COVID-19 Treatment & Prevention
NCT04590274Phase 1Withdrawn
- Sponsor
- International Brain Research Foundation
- Start
- Nov 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19), sponsored by International Brain Research Foundation. Primary endpoint: Percentage of individuals who develop COVID-19 symptoms at 6 months. Planned start Nov 2020; status: withdrawn.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04590274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04590274.